Phase I trial of the mTOR inhibitor everolimus in combination with multi-agent chemotherapy in relapsed childhood acute lymphoblastic leukemia

Potent efficacy of combined PI3K/mTOR and JAK or ABL inhibition in murine xenograft models of Ph-like acute lymphoblastic leukemia

(2016) Sarah K. Tasian et al.   BLOOD

Synergistic Drug Combinations with a CDK4/6 Inhibitor in T-cell Acute Lymphoblastic Leukemia

(2016) Yana Pikman et al.   CLINICAL CANCER RESEARCH

Validation and Implementation of a Custom Next-Generation Sequencing Clinical Assay for Hematologic Malignancies

(2016) Michael J. Kluk et al.   JOURNAL OF MOLECULAR DIAGNOSTICS

The mTORC1 inhibitor everolimus has antitumor activity in vitro and produces tumor responses in patients with relapsed T-cell lymphoma

(2015) T. E. Witzig et al.   BLOOD

A Phase I/II Study of the mTOR Inhibitor Everolimus in Combination with HyperCVAD Chemotherapy in Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia

(2015) N. Daver et al.   CLINICAL CANCER RESEARCH

Rothia Bacteremia: a 10-Year Experience at Mayo Clinic, Rochester, Minnesota

(2014) Poornima Ramanan et al.   JOURNAL OF CLINICAL MICROBIOLOGY

An epigenetic mechanism of resistance to targeted therapy in T cell acute lymphoblastic leukemia

(2014) Birgit Knoechel et al.   NATURE GENETICS

Targeting the PI3K/mTOR Pathway in Pediatric Hematologic Malignancies

(2014) Sarah K. Tasian et al.   Frontiers in Oncology

Use of Allogeneic Hematopoietic Stem-Cell Transplantation Based on Minimal Residual Disease Response Improves Outcomes for Children With Relapsed Acute Lymphoblastic Leukemia in the Intermediate-Risk Group

(2013) Cornelia Eckert et al.   JOURNAL OF CLINICAL ONCOLOGY

Targeting the PI3K/Akt/mTOR signaling pathway in B-precursor acute lymphoblastic leukemia and its therapeutic potential

(2013) L M Neri et al.   LEUKEMIA

Targeting JAK1/2 and mTOR in murine xenograft models of Ph-like acute lymphoblastic leukemia

(2012) S. L. Maude et al.   BLOOD

Minimal residual disease after induction is the strongest predictor of prognosis in intermediate risk relapsed acute lymphoblastic leukaemia – Long-term results of trial ALL-REZ BFM P95/96

(2012) Cornelia Eckert et al.   EUROPEAN JOURNAL OF CANCER

RAD001 (everolimus) induces dose-dependent changes to cell cycle regulation and modifies the cell cycle response to vincristine

(2012) P O Saunders et al.   ONCOGENE

High-Throughput Detection of Actionable Genomic Alterations in Clinical Tumor Samples by Targeted, Massively Parallel Sequencing

(2011) Nikhil Wagle et al.   Cancer Discovery

Effect of mitoxantrone on outcome of children with first relapse of acute lymphoblastic leukaemia (ALL R3): an open-label randomised trial

(2010) Catriona Parker et al.   LANCET

Stage 2 Combination Testing of Rapamycin with Cytotoxic Agents by the Pediatric Preclinical Testing Program

(2010) P. J. Houghton et al.   MOLECULAR CANCER THERAPEUTICS

Potentiating effects of RAD001 (Everolimus) on vincristine therapy in childhood acute lymphoblastic leukemia

(2009) R. Crazzolara et al.   BLOOD

High frequency of PTEN, PI3K, and AKT abnormalities in T-cell acute lymphoblastic leukemia

(2009) A. Gutierrez et al.   BLOOD

Outcome of Patients Treated for Relapsed or Refractory Acute Lymphoblastic Leukemia: A Therapeutic Advances in Childhood Leukemia Consortium Study

(2009) Richard H. Ko et al.   JOURNAL OF CLINICAL ONCOLOGY

mTOR inhibitors are synergistic with methotrexate: an effective combination to treat acute lymphoblastic leukemia

(2008) D. T. Teachey et al.   BLOOD

Chemoimmunotherapy Reinduction With Epratuzumab in Children With Acute Lymphoblastic Leukemia in Marrow Relapse: A Children's Oncology Group Pilot Study

(2008) Elizabeth A. Raetz et al.   JOURNAL OF CLINICAL ONCOLOGY

Reinduction Platform for Children With First Marrow Relapse of Acute Lymphoblastic Leukemia: A Children's Oncology Group Study

(2008) Elizabeth A. Raetz et al.   JOURNAL OF CLINICAL ONCOLOGY

Factors influencing survival after relapse from acute lymphoblastic leukemia: a Children's Oncology Group study

(2008) K Nguyen et al.   LEUKEMIA